Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.